Maintaining Downstream Quality In Multi-Specific Antibody Manufacturing

Source: Cytiva

Bayer Sr. Director, Bioprocess Technologies, Amir Goudarzi, Ph.D., addresses audience questions on downstream multi-specific mAb processing challenges, specifically purification in terms of CPP and QRA, and microbial or thermal degradation, in this segment of the Bioprocess Online Live event, Process Development For A Diverse mAb Pipeline.

access the Video!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online